Literature DB >> 12827639

Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography.

Philip Seeman1, Teresa Tallerico, Françoise Ko.   

Abstract

Because the high-affinity state of the dopamine D2 receptor, D2High, is the functional state of the receptor, has a role in demarcating typical from atypical antipsychotics, and is markedly elevated in amphetamine-sensitized rats, it is important to have a method for the convenient detection of this state by a ligand. The present data show that, in contrast to [(3)H]spiperone or [(3)H]raclopride, [(3)H]domperidone labels D2High sites in the presence of isotonic NaCl in either striatum or cloned D2Long receptors, yielding a dopamine dissociation constant (1.75 nM) in agreement with that found with [(3)H]dopamine. Increased labeling of D2High sites occurred with [(3)H]domperidone after severe disruption of the cells, suggesting that [(3)H]domperidone has better access to the D2 receptor from the cytoplasmic aspect of the cell membrane. The density of the [(3)H]domperidone-labeled D2 receptors was the same as that of the [(3)H]raclopride-labeled D2 receptors, but twice the density of [(3)H]spiperone sites for human cloned D2Long receptors, compatible with the monomer-dimer concept of the D2 receptor. [(3)H]domperidone readily labels the D2High sites in postmortem human brain homogenates. Although [(3)H]spiperone or [(3)H]raclopride can occupy D2High sites, the inability of 1-10 nM dopamine to displace these ligands under isotonic conditions suggests that these ligands may not be suitable for monitoring the physiological high-affinity state of the dopamine D2 receptor by means of [(11)C]methylspiperone or [(11)C]raclopride in humans. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12827639     DOI: 10.1002/syn.10232

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  16 in total

1.  A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics.

Authors:  Benjamin U Nwosu; Bruce Meltzer; Louise Maranda; Carol Ciccarelli; Daniel Reynolds; Laura Curtis; Jean King; Jean A Frazier; Mary M Lee
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

2.  Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis.

Authors:  Philip Seeman; David Weinshenker; Remi Quirion; Lalit K Srivastava; Sanjeev K Bhardwaj; David K Grandy; Richard T Premont; Tatyana D Sotnikova; Patricia Boksa; Mufida El-Ghundi; Brian F O'dowd; Susan R George; Melissa L Perreault; Pekka T Männistö; Siobhan Robinson; Richard D Palmiter; Teresa Tallerico
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

Review 3.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

4.  Domperidone as an unintended antipsychotic.

Authors:  Jack Ferrier
Journal:  Can Pharm J (Ott)       Date:  2014-03

Review 5.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

6.  Further evaluation of the carbon11-labeled D(2/3) agonist PET radiotracer PHNO: reproducibility in tracer characteristics and characterization of extrastriatal binding.

Authors:  Alice Egerton; Ella Hirani; Rabia Ahmad; David R Turton; Diana Brickute; Lula Rosso; Oliver D Howes; Sajinder K Luthra; Paul M Grasby
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

7.  Cocaine self-administration produces a persistent increase in dopamine D2 High receptors.

Authors:  Lisa A Briand; Shelly B Flagel; Philip Seeman; Terry E Robinson
Journal:  Eur Neuropsychopharmacol       Date:  2008-03-04       Impact factor: 4.600

8.  Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization.

Authors:  Min Wang; Lin Pei; Paul J Fletcher; Shitij Kapur; Philip Seeman; Fang Liu
Journal:  Mol Brain       Date:  2010-09-02       Impact factor: 4.041

9.  Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.

Authors:  Ariel Graff-Guerrero; Matthaeus Willeit; Nathalie Ginovart; David Mamo; Romina Mizrahi; Pablo Rusjan; Irina Vitcu; Philip Seeman; Alan A Wilson; Shitij Kapur
Journal:  Hum Brain Mapp       Date:  2008-04       Impact factor: 5.038

Review 10.  The dopaminergic basis of human behaviors: A review of molecular imaging studies.

Authors:  Alice Egerton; Mitul A Mehta; Andrew J Montgomery; Julia M Lappin; Oliver D Howes; Suzanne J Reeves; Vincent J Cunningham; Paul M Grasby
Journal:  Neurosci Biobehav Rev       Date:  2009-05-27       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.